Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Drug Therapy of Supraventricular Tachyarrhythmias—Based on Efficacy or Futility?

Drug Therapy of Supraventricular Tachyarrhythmias—Based on Efficacy or Futility? Abstract The clinical spectrum of supraventricular tachyarrhythmias ranges from infrequent, brief and well tolerated episodes of arrhythmta to attacks resulting in cardiovascular collapse. Many patients have such infrequent episodes that prophylactic or ablative therapy is not indicated. In those with more troublesome symptoms, an initial trial of medical therapy is common unless the arrhythmia has major prognostic or vocational importance. Thus despite the recent advances in catheter ablation techniques there remains a place for antiarrhythmic drug therapy in supraventricular tachyarrhythmias. Furthermore, ablation therapy in atrial fibrillation is currently unable to control arrhythmias except by destruction of rhe normal conduction system. In contrast to the therapy goals in ventricular tachyarrhythmias, safety considerations far outweigh those of efficacy in the drug management of supraventricular tachycardias. Many patients with supraventricular tachyarrhythmias are young and have no serious underlying heart disease. Although symptomatic recurrences of arrhythmia are troublesome, these should be regarded as acceptable if the alternative is serious drug-related toxicity. There are relatively few well conducted clinical trials of the efficacy of drug therapy in supraventricular tachycardia. Existing study data and new trial information on the efficacy of propafenone are reviewed. Supraventricular tachyarrhythmias, antiarrhythmic drugs This content is only available as a PDF. © 1994 The European Society of Cardiology http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Heart Journal Oxford University Press

Drug Therapy of Supraventricular Tachyarrhythmias—Based on Efficacy or Futility?

Cobbe, S., M.
European Heart Journal , Volume 15 (suppl_A) – Apr 1, 1994
Download PDF
5 pages

Loading next page...
 
/lp/oxford-university-press/drug-therapy-of-supraventricular-tachyarrhythmias-based-on-efficacy-or-EkEpj2z2Ni

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Oxford University Press
Copyright
© 1994 The European Society of Cardiology
ISSN
0195-668X
eISSN
1522-9645
DOI
10.1093/eurheartj/15.suppl_A.22
Publisher site
See Article on Publisher Site

Abstract

Abstract The clinical spectrum of supraventricular tachyarrhythmias ranges from infrequent, brief and well tolerated episodes of arrhythmta to attacks resulting in cardiovascular collapse. Many patients have such infrequent episodes that prophylactic or ablative therapy is not indicated. In those with more troublesome symptoms, an initial trial of medical therapy is common unless the arrhythmia has major prognostic or vocational importance. Thus despite the recent advances in catheter ablation techniques there remains a place for antiarrhythmic drug therapy in supraventricular tachyarrhythmias. Furthermore, ablation therapy in atrial fibrillation is currently unable to control arrhythmias except by destruction of rhe normal conduction system. In contrast to the therapy goals in ventricular tachyarrhythmias, safety considerations far outweigh those of efficacy in the drug management of supraventricular tachycardias. Many patients with supraventricular tachyarrhythmias are young and have no serious underlying heart disease. Although symptomatic recurrences of arrhythmia are troublesome, these should be regarded as acceptable if the alternative is serious drug-related toxicity. There are relatively few well conducted clinical trials of the efficacy of drug therapy in supraventricular tachycardia. Existing study data and new trial information on the efficacy of propafenone are reviewed. Supraventricular tachyarrhythmias, antiarrhythmic drugs This content is only available as a PDF. © 1994 The European Society of Cardiology

Journal

European Heart Journal – Oxford University Press

Published: Apr 1, 1994

There are no references for this article.